https://www.gilead.com/news/news-details/2020/gilead-receives-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis
Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely...
Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
complete response letterthe treatmentgileadreceivesfilgotinib